Showing 117 of 117on this page. Filters & sort apply to loaded results; URL updates for sharing.117 of 117 on this page
AnaptysBio announces pricing of $100 million offering | Biotechnology ...
AnaptysBio Describes Technology for the Discovery and Optimization of ...
AnaptysBio Announces Data from Collaboration with BRI | Benaroya ...
AnaptysBio Announces The Appointment Of Dominic Piscitelli As Chief ...
AnaptysBio Shares Approach Critical Juncture as Key Events Loom ...
Anaptysbio logo hi-res stock photography and images - Alamy
AnaptysBio Teases Q2 Split Into RoyaltyCo and Biopharma Spin, Flags ...
AnaptysBio Shares Face Pressure Amid Insider Sale and Strategic Uncertainty
AnaptysBio | LinkedIn
AnaptysBio Announces Strategic Split into Two Public Companies - Stocks ...
AnaptysBio Completes Spin-Off of First Tracks Biotherapeutics
AnaptysBio — AnaptysBio Corporate Presentation — April 2026 — biotech ...
Vanda & AnaptysBio Partner for the Development and Commercialization of ...
After going 0 for 2, AnaptysBio CEO makes immediate exit, leaving a ...
AnaptysBio - Transforming patient health by delivering innovative ...
AnaptysBio on LinkedIn: #anaptysbio
AnaptysBio on LinkedIn: Anaptys Expands Immune Cell Modulator Pipeline ...
AnaptysBio Shares Rise as First Tracks Spin-Off Gains Investor ...
Home - AnaptysBio
AnaptysBio logo in transparent PNG format
AnaptysBio Presents Positive Phase 2b Data for Rosnilimab in Rheumatoid ...
AnaptysBio Aktie: Rally hält an
AnaptysBio on LinkedIn: Novel immune modulator has potential to change ...
AnaptysBio on LinkedIn: #monoclonalantibodies #autoimmune # ...
#btlaagonist #sid2024 #clinicaldermatology | AnaptysBio
AnaptysBio Inc (ANAB) Q1 2025 Earnings: Revenue Surges to $27.8M
AnaptysBio Upgraded After RA Drug Matches Top Therapies In Phase 2 ...
ANAB Stock Price | AnaptysBio Inc. Stock Quote (U.S.: Nasdaq) | MarketWatch
AnaptysBio · GitHub
AnaptysBio shares tumble after legal fight with GSK over cancer drug ...
Equities Analysts Decrease Earnings Estimates for AnaptysBio Inc ...
AnaptysBio - 10-K annual report
AnaptysBio | Biotechnology | The Pharmaletter
AnaptysBio
Advancing the Development of Imsidolimab with AnaptysBio | Indero
AnaptysBio | 10-K: FY2025 Annual Report - Futubull
AnaptysBio (NASDAQ:ANAB) Now Covered by Analysts at BTIG Research ...
AnaptysBio imsidolimab gets FDA orphan drug designation for pustular ...
AnaptysBio » ADC Review
AnaptysBio Charts Path To Split Into Two Companies By 2026 - AnaptysBio ...
Anaptysbio Inc (ANAB) 8-K Earnings Release, Regulated Disclosure - Jan 2026
AnaptysBio Details First Tracks Bio Spin-Off, Jemperli Royalty Surge ...
AnaptysBio CEO abruptly resigns less than a week after mid-stage flop
Anaptys to Present at the Guggenheim SMID Cap Biotech
Hollings Renton Net Worth, Biography, and Insider Trading
Novartis pays up to $1 billion for potential eczema drug | pharmaphorum
Anaptys Completes Separation of First Tracks Biotherapeutics and Now ...
AnaptysBio, Inc. | Avalon Ventures
Top 52 medical and healthcare startups in San Diego
BiotechTV | Bringing the Biotech Sector to Life
AnaptysBio, Inc. - AnnualReports.com
#immunecellmodulators #autoimmunediseases #inflammatorydiseases ...
AnaptysBio:从PD-1到CD122,打造自身免疫疾病的“同类最佳”疗法 $AnaptysBio(ANAB)$ 摘要 ...
GRAPHIC
AnaptysBio: A Prime M&A Target in Immunotherapy with a Robust Pipeline ...
AnaptysBio, Inc. (ANAB): Among the Unstoppable Growth Stocks to Invest ...
AnaptysBio'nun dördüncü çeyrek zararı azaldı - Midas
AnaptysBio, Inc. (ANAB) ANB033 (CD122 antagonist) Virtual Investor ...
New Corporate Member | International Psoriasis Council
AnaptysBio's Bold Split Aims to Unlock Shareholder Value - BriefGlance.com
One-on-One: TDD Talks to Paul Lizzul, MD, PhD, Chief Medical Officer ...
AnaptysBio, Inc. - BioSpace
DelveInsight Business Research LLP on LinkedIn: Pharma News | Amgen ...
AnaptysBio's Strategic Outlook After Clinical Setback
"PD-1, 자가면역 접근" 아납티스, RA 2b상 “증상개선” - 바이오스펙테이터
AnaptysBio's Pivotal Legal Battle and Corporate Split on the Horizon ...
生物科技公司:Anaptysbio Inc.(ANAB) – 美股投資指南
Anaptys to Present at the Guggenheim SMID Cap Biotech Conference | The ...
Momenta Pharmaceuticals Exercises Option to Acquire Novel Antibody ...
AnaptysBio's CEO discusses recent 12 week RA data from the company's PD ...
Tutkimusilmoitus: Keliaakikko – haluaisitko osallistua keliakian ...
Anaptys Partner Search Boosted By Phase III Skin Disease Success
Vanda and Anaptys ink licencing agreement for commercialization of ...
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License ...
AnaptysBio's imsidolimab could pose challenge to Boehringer’s Spevigo ...
AnaptysBio's dermatology drug misses the mark in phase 2 - Biotech Today
AnaptysBio, Inc. 2025 Annual Meeting
Employer Resources: Managing Arthritis at Work | Arthritis Foundation